Galenica (SWX:GALE) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

GALE Panoramica delle azioni

Galenica AG opera come fornitore di servizi sanitari in Svizzera e a livello internazionale.

GALE analisi fondamentale
Punteggio fiocco di neve
Valutazione	4/6
Crescita futura	1/6
Prestazioni passate	4/6
Salute finanziaria	6/6
Dividendi	3/6

Premi

Negoziato a 57.2% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 5.06% all'anno

Gli utili sono cresciuti del 3.1% all'anno negli ultimi 5 anni

Analisi del rischio

Andamento instabile dei dividendi

Galenica AG Concorrenti

Ypsomed Holding

SWX:YPSN

CHF 5.6b

Medacta Group

SWX:MOVE

CHF 2.6b

Sonova Holding

SWX:SOON

CHF 17.4b

MediPal Holdings

TSE:7459

JP¥525.9b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Galenica
Prezzi storici delle azioni
Prezzo attuale dell'azione	CHF 72.25
Massimo di 52 settimane	CHF 78.15
Minimo di 52 settimane	CHF 65.10
Beta	0.19
1Variazione di 1 mese	-3.73%
Variazione a 3 mesi	1.69%
Variazione di 1 anno	3.81%
3Variazione a 3 anni	0.63%
Variazione a 5 anni	33.55%
Variazione dall'IPO	68.02%

Notizie e aggiornamenti recenti

Recent updates

Earnings Not Telling The Story For Galenica AG (VTX:GALE)

Jul 31

Is Galenica (VTX:GALE) Using Too Much Debt?

Jun 16

Galenica AG (VTX:GALE) Investors Are Less Pessimistic Than Expected

Apr 25

We Think The Compensation For Galenica AG's (VTX:GALE) CEO Looks About Right

Apr 04

Slowing Rates Of Return At Galenica (VTX:GALE) Leave Little Room For Excitement

Mar 29

Pinning Down Galenica AG's (VTX:GALE) P/E Is Difficult Right Now

Jan 22

Is There An Opportunity With Galenica AG's (VTX:GALE) 42% Undervaluation?

Jan 04

Returns On Capital At Galenica (VTX:GALE) Have Hit The Brakes

Oct 26

Is Galenica (VTX:GALE) Using Too Much Debt?

Oct 11

Are Investors Undervaluing Galenica AG (VTX:GALE) By 42%?

Sep 26

These 4 Measures Indicate That Galenica (VTX:GALE) Is Using Debt Reasonably Well

Jun 20

Here's What To Make Of Galenica's (VTX:GALE) Decelerating Rates Of Return

Apr 17

We Think Galenica (VTX:GALE) Can Stay On Top Of Its Debt

Mar 12

Returns On Capital At Galenica (VTX:GALE) Have Hit The Brakes

Jan 08

These 4 Measures Indicate That Galenica (VTX:GALE) Is Using Debt Reasonably Well

Nov 28

The Returns At Galenica (VTX:GALE) Aren't Growing

Sep 20

Is Galenica (VTX:GALE) A Risky Investment?

Aug 30

Return Trends At Galenica (VTX:GALE) Aren't Appealing

Jun 15

Galenica (VTX:GALE) Could Easily Take On More Debt

Apr 06

Galenica (VTX:GALE) Has More To Do To Multiply In Value Going Forward

Feb 15

Should You Be Adding Galenica (VTX:GALE) To Your Watchlist Today?

Jan 02

Does Galenica (VTX:GALE) Have A Healthy Balance Sheet?

Nov 30

Returns At Galenica (VTX:GALE) Appear To Be Weighed Down

Oct 24

With EPS Growth And More, Galenica (VTX:GALE) Is Interesting

Sep 25

Galenica (VTX:GALE) Seems To Use Debt Quite Sensibly

Aug 24

Galenica (VTX:GALE) Has More To Do To Multiply In Value Going Forward

Jul 24

If You Like EPS Growth Then Check Out Galenica (VTX:GALE) Before It's Too Late

Jun 12

Investors Met With Slowing Returns on Capital At Galenica (VTX:GALE)

Apr 07

Galenica (VTX:GALE) Seems To Use Debt Quite Sensibly

Mar 25

Galenica AG Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 11

Is Galenica AG (VTX:GALE) The Right Choice For A Smart Dividend Investor?

Feb 27

Are Institutions Heavily Invested In Galenica AG's (VTX:GALE) Shares?

Jan 31

Galenica (VTX:GALE) Shareholders Have Enjoyed A 25% Share Price Gain

Jan 13

Is Galenica (VTX:GALE) Likely To Turn Things Around?

Dec 25

Is Galenica (VTX:GALE) A Risky Investment?

Dec 09

Is Galenica AG (VTX:GALE) An Attractive Dividend Stock?

Nov 24

Rendimenti per gli azionisti

	GALE	CH Healthcare	CH Mercato
7D	-0.7%	2.5%	3.1%
1Y	3.8%	-2.6%	9.2%

Ritorno vs Industria: GALE ha superato il Swiss Healthcare che ha restituito -2.6 % nell'ultimo anno.

Rendimento vs Mercato: GALE ha avuto una performance inferiore al mercato Swiss che ha registrato un rendimento 9.2 % nell'ultimo anno.

Volatilità dei prezzi

Is GALE's price volatile compared to industry and market?
GALE volatility
GALE Average Weekly Movement	2.1%
Healthcare Industry Average Movement	4.5%
Market Average Movement	3.5%
10% most volatile stocks in CH Market	7.5%
10% least volatile stocks in CH Market	1.7%

Prezzo delle azioni stabile: GALE non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 2% ) di GALE è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1927	7,955	Marc Werner	www.galenica.com

Galenica AG opera come fornitore di servizi sanitari in Svizzera e a livello internazionale. Opera attraverso due segmenti, Prodotti e cure e Logistica e IT. Il segmento Prodotti & Cura gestisce farmacie e farmacie partner con i marchi Amavita, Sun Store e Coop Vitality.

Galenica AG Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Galenica con la sua capitalizzazione di mercato?
GALE statistiche fondamentali
Capitalizzazione di mercato	CHF 3.60b
Guadagni(TTM)	CHF 169.68m
Ricavi(TTM)	CHF 3.80b

21.2x

Rapporto P/E

0.9x

Rapporto P/S

GALE è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
GALE Conto economico (TTM)
Ricavi	CHF 3.80b
Costo del fatturato	CHF 3.34b
Profitto lordo	CHF 464.58m
Altre spese	CHF 294.90m
Guadagni	CHF 169.68m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Mar 11, 2025

Utile per azione (EPS)	3.41
Margine lordo	12.22%
Margine di profitto netto	4.46%
Rapporto debito/patrimonio netto	42.9%

Come si è comportato GALE nel lungo periodo?

Vedi performance storica e confronto

Dividendi

3.0%

Rendimento attuale del dividendo

65%

Rapporto di remunerazione

GALE Panoramica delle azioni

Premi

Analisi del rischio

Galenica AG Concorrenti

SWX:YPSN

CHF 5.6b

SWX:MOVE

CHF 2.6b

SWX:SOON

CHF 17.4b

TSE:7459

JP¥525.9b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

First half 2024 earnings released: EPS: CHF1.58 (vs CHF1.49 in 1H 2023)

Earnings Not Telling The Story For Galenica AG (VTX:GALE)

Is Galenica (VTX:GALE) Using Too Much Debt?

Galenica AG (VTX:GALE) Investors Are Less Pessimistic Than Expected

Upcoming dividend of CHF2.20 per share

We Think The Compensation For Galenica AG's (VTX:GALE) CEO Looks About Right

Recent updates

First half 2024 earnings released: EPS: CHF1.58 (vs CHF1.49 in 1H 2023)

Earnings Not Telling The Story For Galenica AG (VTX:GALE)

Is Galenica (VTX:GALE) Using Too Much Debt?

Galenica AG (VTX:GALE) Investors Are Less Pessimistic Than Expected

Upcoming dividend of CHF2.20 per share

We Think The Compensation For Galenica AG's (VTX:GALE) CEO Looks About Right

Slowing Rates Of Return At Galenica (VTX:GALE) Leave Little Room For Excitement

Full year 2023 earnings: EPS exceeds analyst expectations

Galenica AG to Report Fiscal Year 2024 Results on Mar 11, 2025

Pinning Down Galenica AG's (VTX:GALE) P/E Is Difficult Right Now

Galenica AG to Report First Half, 2024 Results on Aug 06, 2024

Is There An Opportunity With Galenica AG's (VTX:GALE) 42% Undervaluation?

Returns On Capital At Galenica (VTX:GALE) Have Hit The Brakes

Is Galenica (VTX:GALE) Using Too Much Debt?

Are Investors Undervaluing Galenica AG (VTX:GALE) By 42%?

First half 2023 earnings released: EPS: CHF1.49 (vs CHF1.59 in 1H 2022)

New minor risk - Financial position

These 4 Measures Indicate That Galenica (VTX:GALE) Is Using Debt Reasonably Well

Galenica AG (SWX:GALE) acquired AD Swiss Net AG.

Galenica AG to Report Fiscal Year 2023 Final Results on Mar 12, 2024

Upcoming dividend of CHF2.20 per share at 2.7% yield

Here's What To Make Of Galenica's (VTX:GALE) Decelerating Rates Of Return

We Think Galenica (VTX:GALE) Can Stay On Top Of Its Debt

Returns On Capital At Galenica (VTX:GALE) Have Hit The Brakes

These 4 Measures Indicate That Galenica (VTX:GALE) Is Using Debt Reasonably Well

Bruno sauter acquired Careproduct AG on Galenica AG (SWX:GALE).

The Returns At Galenica (VTX:GALE) Aren't Growing

Is Galenica (VTX:GALE) A Risky Investment?

First half 2022 earnings released

Galenica AG to Report Q2, 2023 Results on Aug 08, 2023

Galenica AG (SWX:GALE) acquired Aquantic Ltd.

Return Trends At Galenica (VTX:GALE) Aren't Appealing

Galenica AG (SWX:GALE) acquired an unknown stake in Well Gesundheit AG.

Galenica AG, Annual General Meeting, May 03, 2023

Upcoming dividend of CHF2.10 per share

Galenica (VTX:GALE) Could Easily Take On More Debt

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Galenica (VTX:GALE) Has More To Do To Multiply In Value Going Forward

Should You Be Adding Galenica (VTX:GALE) To Your Watchlist Today?

Does Galenica (VTX:GALE) Have A Healthy Balance Sheet?

Returns At Galenica (VTX:GALE) Appear To Be Weighed Down

With EPS Growth And More, Galenica (VTX:GALE) Is Interesting

Galenica (VTX:GALE) Seems To Use Debt Quite Sensibly

First half 2021 earnings released: EPS CHF1.60 (vs CHF1.34 in 1H 2020)

Galenica (VTX:GALE) Has More To Do To Multiply In Value Going Forward

If You Like EPS Growth Then Check Out Galenica (VTX:GALE) Before It's Too Late

Upcoming dividend of CHF1.80 per share

Investors Met With Slowing Returns on Capital At Galenica (VTX:GALE)

Galenica (VTX:GALE) Seems To Use Debt Quite Sensibly

Galenica AG Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2020 earnings released: EPS CHF3.48 (vs CHF2.54 in FY 2019)

Revenue and earnings beat expectations

New 90-day low: CHF57.90

Is Galenica AG (VTX:GALE) The Right Choice For A Smart Dividend Investor?

Are Institutions Heavily Invested In Galenica AG's (VTX:GALE) Shares?

Galenica AG to Report First Half, 2021 Results on Aug 03, 2021

Galenica (VTX:GALE) Shareholders Have Enjoyed A 25% Share Price Gain

Is Galenica (VTX:GALE) Likely To Turn Things Around?

Biofrontera Pharma GmbH Enters into License and Supply Agreement with Galenica AB for the Marketing of Ameluz in Scandinavia